Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

'Biosimilar' drugs poised to penetrate market

Nature volume 468, pages 18–19 (2010)Cite this article

Subjects

Draft regulations will pave the way for copycat antibodies and other large molecules.

When is a copy good enough to be treated as the real thing? In recent days, regulators on both sides of the Atlantic have been grappling with the question as they try to develop guidelines that will expand the development of 'biosimilar' drugs: copycat versions of complex biological drugs, such as antibodies and other therapeutic proteins.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related external links

EMA biosimilars

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ledford, H. 'Biosimilar' drugs poised to penetrate market. Nature 468, 18–19 (2010). https://doi.org/10.1038/468018a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/468018a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research